Skip to main content
SpringerLink
Log in

Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate

  • Original Articles
  • Published:
Urological Research Aims and scope Submit manuscript

Summary

This paper presents an approach for the assessment of the androgen receptor (AR) status in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) tissues. Evaluation of AR was carried out in both soluble and nuclear fractions by a standard competition method, using tritiated mibolerone as radioligand. Based on our experience with breast and endometrial cancer, this approach focused on both type I (high affinity, low capacity) binding sites, aiming mainly at establishing a putative “functional” receptor mechanism, i.e., the presence of type I AR in both cytosol and nucleus. Ancillary studies were carried out to exclude a potential overestimation of the AR content by interference with other steroid receptors, namely, progesterone (PgR) or glucocorticoid (GcR) receptors. Results showed that the interaction by PgR or GcR upon AR measurement was not relevant. The distribution of AR, namely the percent of positivity either in a single or in both cell compartments, was not significantly different in BPH (N=32) or PCa (N=24) tissues. For type I binding, the percent of positivity in both soluble and nuclear fractions (i.e., the “functional” AR status) was very close to that observed for other endocrine-related tumors, like breast cancer. Concentrations of type I AR appeared significantly higher in PCa than in BPH tissues; this was true for both soluble and nuclear fractions. In contrast, no significant difference was found in type II AR concentrations in either cell fraction. Nuclear type I AR proved to be positive in the great majority (more than 90%) of both PCa and BPH specimens; thus, this study does not support the hypothesis that nuclear AR may have a prognostic value, as previously suggested. Until long-term follow-up data on PCa patients are available, the predictive value of AR status, as estimated by this approach, cannot be assessed; however, in parallel with the studies carried out on estrogen receptor status in breast cancer patients, we suggest that a “functional” AR status is better indicated by the presence of type I binding in both cell fractions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Huggins C, Hodges CV (1941) Studies on prostatic cancer. 1. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293

    Google Scholar 

  2. Hansson V, Tveter KJ, Attramadal A, Torgersen O (1971) Androgenic receptors in human benign nodular prostatic hyperplasia. Acta Endocrinol 68:79

    Google Scholar 

  3. Mobbs BG, Johnson IE, Connoly JG, Clark AF (1978) Androgen receptor assay in human benign and malignant prostatic tumor cytosol using protamine sulphate precipitation. J Steroid Biochem 9:289

    Google Scholar 

  4. Lieskovsky G, Bruchovsky N (1979) Assay of nuclear androgen receptor in human prostate. J Urol 121:54

    Google Scholar 

  5. Shain SA, Boesel RW, Lamm DL, Radwin HM (1980) Cytoplasmic and nuclear androgen receptor content of normal and neoplastic human prostates and lymph node metastases of human prostatic adenocarcinoma. J Clin Endocrinol Metab 50:704

    Google Scholar 

  6. Trachtenberg J, Bujnovszky P, Walsh PC (1982) Androgen receptor content of normal and hyperplastic human prostate. J Clin Endocrinol Metab 54:7

    Google Scholar 

  7. Ekman P (1982) The application of steroid receptor assay in human prostate cancer research and clinical management (review). Anticancer Res 2:163

    Google Scholar 

  8. Brendler CB, Isaacs JT, Follansbee AL, Walsh PC (1984) The use of multiple variables to predict response to endocrine therapy in carcinoma of the prostate: a preliminary report. J Urol 131:694

    Google Scholar 

  9. Fentie DD, Lakey WH, McBlain WA (1986) Applicability of nuclear androgen receptor quantification to human prostatic adenocarcinoma. J Urol 135:167

    Google Scholar 

  10. Kyprianou N, Williams H, Peeling WB, Davies P, Griffiths K (1986) Evaluation of biopsy techniques for androgen receptor assay in human prostatic tissue. Br J Urol 58:41

    Google Scholar 

  11. van Aubel OGJM, Bold-de Vries J, Blankenstein MA, ten Kate FJ, Schröder FH (1985) Nuclear androgen receptor content in biopsy specimens from histologically normal, hyperplastic and cancerous human prostatic tissue. Prostate 6:185

    Google Scholar 

  12. Ghanadian R, Auf G, Williams G, Davies A, Richards B (1981) Predicting the response of prostatic carcinoma to endocrine therapy. Lancet II:1418

    Google Scholar 

  13. Trachtenberg J, Walsh PC (1982) Correlation of prostatic nuclear androgen receptor content with duration of response and survival following hormonal therapy in advanced prostatic cancer. J Urol 127:466

    Google Scholar 

  14. Pertschuk LP, Eisenberg KB, Macchia RJ, Feldman JG (1985) Heterogeneity of steroid binding sites in prostatic carcinoma: morphological demonstration and clinical implications. Prostate 6:35

    Google Scholar 

  15. Clark JH, Peck EJ Jr (1979) Female sex steroids receptors and function. In: Gross F et al. (eds) Monographs in endocrinology, Vol 14. Springer, Berlin Heidelberg New York

    Google Scholar 

  16. Lopes MTP, Liberato MH, Widman A, Brentani MM (1987) Occupied and unoccupied type II estrogen binding sites in human breast cancer. J Steroid Biochem 26:219

    Google Scholar 

  17. Turcotte G, Chapdelaine A, Roberts KD, Chevalier S (1988) Androgen binding as evidenced by a whole cell assay system using cultured canine prostatic epithelial cells. J Steroid Biochem 29:69

    Google Scholar 

  18. Chevalier S, Turcotte G, McKercher G, Boulanger P, Chapdelaine A (1990) Steroid metabolism and binding in relation to prostatic cell growth and differentiation in vitro. Ann NY Acad Sci 595:173

    Google Scholar 

  19. Laing LM, Smith DC, Calman KC, Smith MG, Leake RE (1977) Nuclear estrogen receptors and treatment of breast cancer. Lancet II:168

    Google Scholar 

  20. Thorsen T (1979) Occupied and unoccupied nuclear oestradiol and progesterone cytosol receptors. J Steroid Biochem 10:661

    Google Scholar 

  21. Leake RE, Habib F (1987) Steroid hormone receptors: assay and characterization. In: Green B, Leake RE (eds) Steroid hormones: a practical approach. IRL Press, Oxford, p 67

    Google Scholar 

  22. Castagnetta L, LoCasto M, Mercadante T, Polito L, Cowan S, Leake RE (1983) Intratumoural variation of oestrogen receptor status in endometrial cancer. Br J Cancer 47:261

    Google Scholar 

  23. Castagnetta L, Traina A, Di Carlo A, Latteri AM, Carruba G, Leake RE (1987) Heterogeneity of soluble and nuclear oestrogen receptor status of involved nodes in relation to primary breast cancer. Eur J Cancer Clin Oncol 23:31

    Google Scholar 

  24. Leake RE, Laing L, Smith DC (1979) The role of oestrogen nuclear receptor measurements in the management of breast cancer. In: King RJB (ed) Steroid receptor assays in human breast cancer. Alpha Omega, Cardiff, p 73

    Google Scholar 

  25. Leake RE, Laing L, McArdle C, Smith DC (1981) Soluble and nuclear oestrogen receptor status in human breast cancer in relation to prognosis. Br J Cancer 43:67

    Google Scholar 

  26. Castagnetta L, LoCasto M, Granata OM, Calabrò M, Ciaccio M, Leake RE (1987) Soluble and nuclear oestrogen receptors status of advanced endometrial cancer in relation to subsequent prognosis. Br J Cancer 55:543

    Google Scholar 

  27. Castagnetta L, Traina A, Di Carlo A, Carruba G, LoCasto M, Mesiti M, Leake RE (1989) Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer? Br J Cancer 59:636

    Google Scholar 

  28. Barnes DM, Skinner LG, Ribeiro GG (1979) Triple hormone-receptor assay: a more accurate predictive tool for the treatment of advanced breast cancer. Br J Cancer 40:682

    Google Scholar 

  29. Hahnel P, Partridge RR, Gavel L, Twaddle E, Rabdizal T (1980) Nuclear and cytoplasmic estrogen receptors and progesterone receptors in breast cancer. Eur J Cancer Clin Oncol 16:1027

    Google Scholar 

  30. Leake RE, Laing L, Calman KC, Maebeth FR, Crawford D, Smith DC (1981) Oestrogen receptor status and endocrine therapy of breast cancer: response rates and status stability. Br J Cancer 43:59

    Google Scholar 

  31. Castagnetta L, Carruba G, Calabrò M, Polito L, Blasi L, Pavone-Macaluso M (1991) Androgen receptor assays in specimens of prostatic tissue obtained by transurethral resection and transvesical adenomectomy. Urol Res 19:337

    Google Scholar 

  32. Crawford D, Cowan S, Hyder S, McMenamin M, Smith D, Leake RE (1984) A new storage procedure for tumor biopsies prior to estrogen receptor measurement. Cancer Res 44:2348

    Google Scholar 

  33. Schilling K, Liao S (1984) The use of radioactive 7alpha, 17alpha-dimethyl-19-nortestosterone (Mibolerone) in the assay of androgen receptors. Prostate 5:581

    Google Scholar 

  34. Jänne O, Kontula K, Vihko R (1976) Progestin receptors in human tissues: concentrations and binding kinetics. J Steroid Biochem 7:1061

    Google Scholar 

  35. Brinkman AO, Bolt J, van Steenbrugge GJ, Kuiper GG, Boer W de, Mulder E (1987) Characterization of androgen receptors in a transplantable human prostatic adenocarcinoma (PC-82). Prostate 10:133

    Google Scholar 

  36. Petra PH, Que BG, Namkung PC, Ross JB, Charbonneau H, Walsch KA, Griffin PR, Shabanowitz J, Hunt DF (1988) Affinity labeling, molecular cloning and comparative amino acid sequence analyses of sex steroid-binding protein of plasma. A multidisciplinary approach for understanding steroid-protein interaction and its physiological role. Ann NY Acad Sci 538:10

    Google Scholar 

  37. Lowry OH, Rosenbrough NJ, Farr AL, Randall J (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265

    Google Scholar 

  38. Burton KA (1956) A study of the conditions and mechanism of the diphenylamine reaction for the colorimetric estimation of deoxyribonucleic acid. Biochem J 62:315

    Google Scholar 

  39. Hawkins EF, Lieskrovsky G, Markland FS (1981) Molybdate and the measurement of androgen receptors in prostate cancer. J Clin Endocrinol Metab 53:456

    Google Scholar 

  40. Smith J, Chisholm GD, Habib FK (1983) Towards a reproducible method of estimating androgen receptors in human prostate. J Steroid Biochem 18:531

    Google Scholar 

  41. Benson RC Jr, Utz DC, Holicky E, Veneziale CM (1985) Androgen receptor binding activity in human prostate cancer. Cancer 55:382

    Google Scholar 

  42. Bowman SP, Barnes D, Blacklock NJ, Sullivan PJ (1986) Regional variation of cytosol androgen receptors throughout the diseased human prostate gland. Prostate 8:167

    Google Scholar 

  43. Hiipakka RA, Liao S (1984) Modulation of androgen receptor activity in the rat ventral prostate. Ann NY Acad Sci 438:54

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hormone Biochemistry Laboratory, University School of Medicine, Policlinic, Palermo, Italy

    L. Castagnetta, G. Carruba & E. Fecarotta

  2. Institute of Urology, University School of Medicine, Policlinic, Palermo, Italy

    M. Pavone-Macaluso

  3. Experimental Oncology and Molecular Endocrinology Unit, Scientific Tumor Institute (IST Genova), Palermo Branch, Palermo, Italy

    M. Lo Casto & R. Cusimano

Authors
  1. L. Castagnetta
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Carruba
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Fecarotta
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Lo Casto
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. R. Cusimano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Pavone-Macaluso
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Castagnetta, L., Carruba, G., Fecarotta, E. et al. Soluble and nuclear type I and II androgen-binding sites in benign hyperplasia and cancer of the human prostate. Urol. Res. 20, 127–132 (1992). https://doi.org/10.1007/BF00296524

Download citation

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00296524

Key words

Search

Navigation